SBIO.L's Sortino Ratio of 3.57 indicates that for each unit of downside volatility, it generates 3.57 units of excess return. The ratio is calculated using historical daily returns over the past 12 months (as of Jun 26, 2026).
Unlike other measures, Sortino only focuses on downside volatility (losses), making it particularly useful for investors more concerned about protecting against drawdowns than overall price swings.
SBIO.L Sortino Ratio Rank
SBIO.L ranks above 89.1% of all investments in our database based on Sortino Ratio over the past 12 months, demonstrating exceptional downside-adjusted returns. Securities are ranked from 0 (worst) to 100 (best).
What moves the rank
- Strong returns with minimal downside volatility → Higher rank
- Severe or frequent drawdowns → Lower rank
- Upside volatility → No impact (Sortino doesn't penalize upside swings)
What you can do with this information
- Suitable as a core holding given strong downside protection
- Monitor rank changes to detect weakening downside characteristics
- Exceptional risk-adjusted profile supports larger position sizes
- Compare with category peers to assess whether strength is investment-specific or category-wide
SBIO.L Sortino Ratio Market Positioning
The chart shows SBIO.L's Sortino Ratio relative to all ETFs on our platform, with color zones indicating percentile rankings. Higher ratios indicate better downside-adjusted returns.
- Red zone (bottom 25%): 1.32 or lower
- Yellow zone (middle 50%): 1.32 to 2.96
- Green zone (top 25%): 2.96 or higher
- Top 1%: 14.86+
- Median: 2.23 — half of all investments score higher
How it compares to other similar ETFs
The table compares Invesco Nasdaq Biotech UCITS ETF's Sortino Ratio with other ETFs in the Health & Biotech Equities category across multiple time periods, showing how SBIO.L's risk-adjusted performance compares to similar funds.
Data shows 1-, 5-, and 10-year periods, plus each fund's all-time average, as of Jun 26, 2026.
| Symbol | Name | 1Y Sortino Ratio | 5Y Sortino Ratio | 10Y Sortino Ratio | All Time Sortino Ratio |
|---|---|---|---|---|---|
| BTEK.L | iShares Nasdaq US Biotechnology UCITS ETF | 3.88 | |||
| FBT.L | First Trust NYSE Arca Biotechnology UCITS ETF Acc | 3.87 | |||
| SBIO.L | Invesco Nasdaq Biotech UCITS ETF | 3.57 | |||
| BTEE.L | iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | 3.56 | |||
| GNOG.L | Global X Genomics & Biotechnology UCITS ETF | 3.41 | |||
| BIGT.L | L&G Pharma Breakthrough UCITS ETF | 3.09 | |||
| WBIO.L | WisdomTree BioRevolution UCITS ETF USD Acc | 3.05 | |||
| DOCG.L | L&G Healthcare Breakthrough UCITS ETF | 2.72 | |||
| DRDR.L | iShares Healthcare Innovation UCITS ETF USD (Acc) | 2.64 | |||
| DOCT.L | L&G Healthcare Breakthrough UCITS ETF | 2.41 |
Historical Sortino Ratio
The chart shows SBIO.L's rolling Sortino ratio over time compared to your chosen benchmark. Rising trends indicate improving returns relative to downside risk, while declining trends may signal deteriorating risk-adjusted performance or increased volatility during market stress. Use multiple timeframes to distinguish short-term fluctuations from long-term patterns.
Identify market cycles by observing when SBIO.L consistently outperforms (line above benchmark), underperforms (below benchmark), or aligns with the benchmark.
Loading charts...
IHow does SBIO.L fit in your portfolio?
Add your other holdings to see your portfolio's Sortino Ratio and find out.
Analyze Your Portfolio